# Question 18

**Type:** Clinical Data

**Question:** What are the most frequently administered systemic therapy regimens for lung cancer patients in the MSK-CHORD Study?

**Answer:**

Perfect! Now I have comprehensive data. Let me provide a complete answer to the user.

## Most Frequently Administered Systemic Therapy Regimens for Lung Cancer Patients in MSK-CHORD Study

Based on the MSK-CHORD Study (MSK, Nature 2024) data, here are the key findings for **Non-Small Cell Lung Cancer (NSCLC)** patients:

### **Study Overview:**
- **Total NSCLC patients:** 7,809
- **Patients receiving systemic therapy:** 5,952 (76.2%)
- **Total treatment courses:** 20,273

### **Top 30 Most Frequently Administered Systemic Therapy Regimens:**

| Rank | Regimen | Therapy Type | Treatment Courses | Patients |
|------|---------|--------------|-------------------|----------|
| 1 | **Carboplatin** | Chemotherapy | 1,819 | 1,720 |
| 2 | **Osimertinib** | Targeted | 1,338 | 1,071 |
| 3 | **Pemetrexed** | Chemotherapy | 1,261 | 1,181 |
| 4 | **Pembrolizumab** | Immunotherapy | 1,102 | 992 |
| 5 | **Carboplatin + Pemetrexed** | Chemotherapy | 907 | 888 |
| 6 | **Gemcitabine** | Chemotherapy | 825 | 798 |
| 7 | **Erlotinib** | Targeted | 804 | 486 |
| 8 | **Nivolumab** | Immunotherapy | 667 | 616 |
| 9 | **Cisplatin** | Chemotherapy | 642 | 633 |
| 10 | **Bevacizumab** | Biologic | 596 | 522 |
| 11 | **Docetaxel** | Chemotherapy | 595 | 581 |
| 12 | **Megestrol** | Hormone | 554 | 497 |
| 13 | **Cisplatin + Pemetrexed** | Chemotherapy | 486 | 482 |
| 14 | **Carboplatin + Paclitaxel** | Chemotherapy | 442 | 432 |
| 15 | **Bevacizumab + Pemetrexed** | Biologic | 355 | 332 |
| 16 | **Crizotinib** | Targeted | 344 | 271 |
| 17 | **Etoposide** | Chemotherapy | 340 | 301 |
| 18 | **Pembrolizumab + Pemetrexed** | Immunotherapy | 311 | 301 |
| 19 | **Paclitaxel** | Chemotherapy | 281 | 274 |
| 20 | **Gemcitabine + Vinorelbine** | Chemotherapy | 281 | 276 |
| 21 | **Paclitaxel Protein-Bound** | Chemotherapy | 268 | 256 |
| 22 | **Atezolizumab** | Immunotherapy | 250 | 238 |
| 23 | **Ramucirumab** | Biologic | 249 | 244 |
| 24 | **Durvalumab** | Immunotherapy | 247 | 239 |
| 25 | **Anastrozole** | Hormone | 246 | 136 |
| 26 | **Alectinib** | Targeted | 226 | 198 |
| 27 | **Carboplatin + Pembrolizumab + Pemetrexed** | Chemotherapy | 218 | 216 |
| 28 | **Afatinib** | Targeted | 214 | 192 |
| 29 | **Docetaxel + Ramucirumab** | Chemotherapy | 185 | 184 |
| 30 | **Vinorelbine** | Chemotherapy | 180 | 179 |

### **Therapy Type Distribution:**

| Therapy Type | Treatment Courses | Patients | % of Total Courses |
|--------------|-------------------|----------|-------------------|
| **Chemotherapy** | 10,157 | 4,636 | 50.1% |
| **Targeted Therapy** | 3,987 | 2,120 | 19.7% |
| **Immunotherapy** | 2,796 | 2,375 | 13.8% |
| **Biologic** | 1,810 | 1,378 | 8.9% |
| **Hormone Therapy** | 1,523 | 865 | 7.5% |

### **Key Insights:**

1. **Platinum-based chemotherapy** remains the most common treatment approach, with carboplatin and cisplatin combinations being heavily utilized
2. **Osimertinib** is the most frequently used targeted therapy, reflecting its importance in EGFR-mutant NSCLC
3. **Pembrolizumab** leads immunotherapy usage, consistent with its broad approval in NSCLC
4. **Combination regimens** are common, particularly:
   - Carboplatin + Pemetrexed (standard first-line for non-squamous NSCLC)
   - Carboplatin + Paclitaxel (standard for squamous NSCLC)
   - Carboplatin + Pembrolizumab + Pemetrexed (chemoimmunotherapy)

---

## Model Information
**Model:** anthropic:claude-sonnet-4-5-20250929
**Provider:** Anthropic
**Max Tokens:** 4096

---

*Generated on 2026-01-28 20:41:24*